Overview: Acylcarnitine C3 TestIntroduction: The Acylcarnitine C3 Test helps diagnose Propionic or Methylmalonic Acidemia, rare disorders causing vomiting, lethargy, or developmental delays due to the body's inability to process certain proteins, aiding early treatment. With a prevalence of 1 in 50,000 to 1 in 100,000, these conditions are more common in certain populations like those of Hispanic or African descent, requiring prompt diagnosis to prevent metabolic crises. Following 2023 ACMG guidelines, it uses tandem mass spectrometry (MS/MS) for high specificity, supporting metabolic screening. This test is crucial for diagnosis, treatment planning, and improving outcomes in biochemistry, particularly in neonatal intensive care units.
Other Names: C3 Assay, Propionylcarnitine Test.
FDA Status: Laboratory-developed test (LDT), meeting biochemistry standards for accuracy.
Historical Milestone: Acylcarnitine testing started in the 1990s with metabolic research by Bridget Wilcken, focusing on organic acidemias in newborns. Tandem MS advancements in the 2000s by Sciex improved detection of C3 carnitine, surpassing earlier gas chromatography-mass spectrometry (GC-MS) methods that required larger sample volumes and were less sensitive.
Purpose: Measures C3 acylcarnitine levels to diagnose Propionic or Methylmalonic Acidemia, guides protein restriction and vitamin B12 therapy, and evaluates patients with vomiting, lethargy, or developmental delays, aiming to prevent life-threatening acidosis or strokes.
Test Parameters: C3 acylcarnitine levels
Pretest Condition: Fasting preferred for 6-8 hours to assess baseline metabolism and detect abnormalities. Collect dried blood spot, plasma, or serum. Report history of vomiting, lethargy, or developmental issues.
Specimen: Dried Blood Spot (filter paper, 3-5 spots), Plasma (NaHep, 2-4 mL), Serum (SST, 2-5 mL); 2 mL plasma in Na Heparin tube or dried blood spot on filter paper. Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 1 week
Sample Stability at Frozen: 1 month
Medical History: Document vomiting, lethargy, or developmental delays. Include dietary history, recent infections, or family history of metabolic disorders, noting any protein-rich diet exposure that could trigger symptoms.
Consent: Written consent required, detailing the test's purpose, acidemia risks (e.g., coma, stroke), and potential risks of sample collection, emphasizing neonatal screening and genetic counseling to inform family planning.
Procedural Considerations: Uses tandem mass spectrometry (MS/MS) to measure C3 levels, requiring laboratories with ABI 3200 systems and trained technicians to handle dried blood spots. Results are available in 2-3 days, supporting neonatal care. Performed in labs with sample drying protocols and temperature control to prevent degradation and ensure accurate metabolite detection.
Factors Affecting Result Accuracy: Improper drying, contamination with skin oils, or exposure to heat can affect results. Protein intake, medications, or concurrent illness may alter levels, necessitating controlled conditions and clinical correlation to avoid misdiagnosis.
Clinical Significance: Elevated C3 confirms Propionic or Methylmalonic Acidemia, guiding dietary protein restriction and cobalamin therapy to stabilize metabolism. A child with early treatment might avoid metabolic stroke, while untreated cases can lead to death or severe neurological damage. Normal levels may require genetic testing (e.g., MMUT) to rule out carriers or alternative diagnoses.
Specialist Consultation: Consult a metabolic specialist or pediatrician for result interpretation and management, particularly for infants or those with family history, where dietary adjustments and emergency protocols are critical to prevent crises.
Additional Supporting Tests: Urine organic acids, MMACHC gene analysis, or plasma amino acids to confirm diagnosis and assess vitamin B12 status, aiding in personalized care and monitoring long-term outcomes.
Test Limitations: Non-specific for disorder type (Propionic vs. Methylmalonic); clinical correlation with symptoms and genetics is needed. Sensitivity varies with metabolic state, requiring repeat testing during symptomatic periods.
References: ACMG Guidelines, 2023; Journal of Inherited Metabolic Disease, Fenton WA, 2022.
